AEterna Zentaris Inc. (USA) - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
AEZS Nasdaq 8731 https://www.zentaris.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for AEterna Zentaris Inc. (USA)

Aeterna Zentaris Shelves Early-Stage Vaccine Programs, Including COVID-19 - Jan 17th, 2023 5:53 pm
Aeterna Zentaris Provides Business Update and Outlines Key Upcoming Milestones - Jan 17th, 2023 1:05 pm
JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th - Jan 11th, 2023 6:00 pm
Aeterna Zentaris to Present at the Virtual Investor 2023 Companies to Watch Event - Jan 10th, 2023 1:05 pm
Aeterna Zentaris (AEZS) Reports Q3 Loss, Tops Revenue Estimates - Nov 3rd, 2022 2:15 pm
Aeterna Zentaris Reports Third Quarter 2022 Financial Results - Nov 3rd, 2022 12:05 pm
Aeterna Zentaris Set to Regain Full Rights to Macrilen™ (Macimorelin) in U.S. and Canada from Novo Nordisk - Aug 29th, 2022 12:00 pm
Aeterna Zentaris Reports Second Quarter 2022 Financial Results and Recent Highlights - Aug 3rd, 2022 9:30 pm
CytomX Therapeutics (CTMX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Jul 28th, 2022 2:02 pm
Aeterna Zentaris Announces Effective Date of Share Consolidation - Jul 18th, 2022 9:06 pm
Aeterna Zentaris Announces Shareholder Approval of Share Consolidation - Jul 15th, 2022 8:15 pm
Aeterna Zentaris Announces Further Adjournment of Shareholder Meeting - Jul 6th, 2022 8:05 pm
Aeterna Zentaris Announces Results of Annual Meeting of Shareholders - Jun 21st, 2022 8:01 pm
Aeterna Zentaris Achieves Proof-of-Concept for the Treatment of NMOSD with AIM Biologicals Program - Jun 13th, 2022 12:00 pm
Aeterna Zentaris to Present at the JMP Securities Life Sciences Conference - Jun 9th, 2022 12:00 pm
Here's Why We're Watching Aeterna Zentaris' (TSE:AEZS) Cash Burn Situation - Jun 3rd, 2022 10:58 am
Aeterna Zentaris’ Licensing Partner, Consilient Health Announces European Launch of Ghryvelin™ (macimorelin) for Diagnosing Adult Growth Hormone Deficiency - May 25th, 2022 12:00 pm
Aeterna Zentaris to Present at the H.C. Wainwright Global Investment Conference - May 18th, 2022 12:00 pm
Aeterna Zentaris Announces Virtual 2022 Meeting of Shareholders and Urges Shareholders to Vote in Favor of the Proposed Share Consolidation - May 16th, 2022 12:00 pm
Update on Positive Pre-Clinical Results from AIM Biologicals Development Program for the Potential Treatment of Parkinson’s Disease - May 12th, 2022 12:05 pm